BridgeBio Pharma, Inc. Increase (Decrease) in Accounts Receivable
BridgeBio Pharma, Inc. (BBIO) reported Increase (Decrease) in Accounts Receivable of $115.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-10
- BridgeBio Pharma, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $49.26M.
- BridgeBio Pharma, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $65.78M, a 40.49% decline year-over-year.
- BridgeBio Pharma, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $22.93M, a 440.20% increase year-over-year.
- BridgeBio Pharma, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $39.65M.
- BridgeBio Pharma, Inc. increase (decrease) in accounts receivable for fiscal 2025 was $134.72M, a 4434.57% increase from fiscal 2024.
- BridgeBio Pharma, Inc. increase (decrease) in accounts receivable for fiscal 2024 was $2.97M.
- BridgeBio Pharma, Inc. increase (decrease) in accounts receivable for fiscal 2023 was -$15.33M.
- BridgeBio Pharma, Inc. increase (decrease) in accounts receivable for fiscal 2022 was -$15.17M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $49.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $115.04M 10-Q · filed 2026-08-10 | $137.97M derived: sum of 3 quarters · filed 2026-08-10 | $177.62M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $65.78M 10-Q · filed 2026-05-07 | $88.71M derived: sum of 2 quarters · filed 2026-05-07 | $128.36M derived: sum of 3 quarters · filed 2026-05-07 | $89.96M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $22.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $62.58M derived: sum of 2 quarters · filed 2026-02-24 | $24.18M derived: sum of 3 quarters · filed 2026-08-10 | $134.72M 10-K · filed 2026-02-24 |
| 2025-09-30 | $39.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $1.25M derived: sum of 2 quarters · filed 2026-08-10 | $111.80M 10-Q · filed 2025-10-29 | $116.04M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$38.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $72.15M 10-Q · filed 2026-08-10 | $76.39M derived: sum of 3 quarters · filed 2026-08-10 | $76.21M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $110.54M 10-Q · filed 2026-05-07 | $114.79M derived: sum of 2 quarters · filed 2026-05-07 | $114.61M derived: sum of 3 quarters · filed 2026-05-07 | -$120.23M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $4.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $4.06M derived: sum of 2 quarters · filed 2026-02-24 | -$230.77M derived: sum of 3 quarters · filed 2026-02-24 | $2.97M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$182.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | -$235.02M derived: sum of 2 quarters · filed 2025-10-29 | -$1.27M 10-Q · filed 2025-10-29 | |
| 2024-06-30 | -$234.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$1.09M 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | $233.74M 10-Q · filed 2025-04-29 | |||
| 2023-12-31 | -$15.33M 10-K · filed 2026-02-24 | |||
| 2022-12-31 | -$15.17M 10-K · filed 2025-02-20 | |||
| 2021-06-30 | $1.04M 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |